Corbus Pharmaceuticals Holding
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +194.8% | +27.7% | +97.6% | +649.5% | -89.1% | -77.6% | -100.0% | – | – | – | |
| – | +369.0% | +162.1% | +68.7% | +86.7% | +84.3% | -99.9% | +1,568.1% | -9.2% | +1,994.8% | -98.1% | -61.2% | |
| – | – | – | – | – | – | – | -119.2% | – | – | – | – | |
| – | +369.0% | +162.1% | +68.7% | +86.7% | +84.3% | +9.7% | -62.9% | -55.7% | +93.1% | +3.4% | +117.5% | |
| – | +159.7% | +78.8% | +38.8% | +44.5% | +82.5% | +20.5% | -28.3% | -8.5% | -25.6% | +18.6% | -7.8% | |
| – | +259.0% | +130.4% | +59.9% | +75.9% | -61.6% | +436.1% | -56.4% | -39.6% | +35.2% | +6.8% | +77.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -89.8% | -100.0% | – | -100.0% | – | +5,305.3% | +78.0% | +16.5% | +37.1% | -36.0% | -100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -89.8% | +458.1% | -3,014.4% | – | -313.7% | – | -350.6% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.